Intranasal immunization with single-dose vaccine based on recombinant influenza virus H1N1 expressing the extracellular domain of respiratory syncytial virus G protein induces robust immunity and protection in mice
10.3760/cma.j.cn112309-20240111-00015
- VernacularTitle:表达呼吸道合胞病毒G蛋白胞外区的重组H1N1流感病毒单剂滴鼻免疫可在小鼠诱导强免疫应答与保护
- Author:
Ruiwen HAN
1
;
Donghong WANG
;
Tangqi WANG
;
Xueting CHENG
;
Jialuo BING
;
Chengcheng ZHAI
;
Shucai SUN
;
Yao DENG
;
Baoying HUANG
;
Wenjie TAN
Author Information
1. 温州医科大学检验医学院 生命科学学院，浙江省医学遗传学重点实验室，温州 325035
- Keywords:
Respiratory syncytial virus;
Influenza virus;
Virus vector;
G attachment protein
- From:
Chinese Journal of Microbiology and Immunology
2024;44(2):93-100
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To construct a novel respiratory syncytial virus (RSV) vaccine based on a recombinant influenza virus vector and evaluate its immune protective effects in mice.Methods:A recombinant H1N1 influenza A virus (IAV) expressing the extracellular domain (Gecto) of RSV A2 G protein was constructed and rescued, named as PR8NAGecto/WSN. After in vitro verification of the Gecto expression and PR8NAGecto/WSN growth kinetics, a single dose of PR8NAGecto/WSN was used to immunize BALB/c mice through intranasal administration to evaluate the efficacy of PR8NAGecto/WSN by assessing humoral (IgG, neutralizing antibody), mucosal (IgA) and cellular immunity (IFN-γ ELISPOT). Four weeks after immunization, the mice were challenged with RSV A2 or RSV B9320 to evaluate the protective effects of PR8NAGecto/WSN by analyzing mouse body weight changes, lung tissue virus titers and pathological changes. Results:A single-dose intranasal immunization with PR8NAGecto/WSN induced robust humoral, mucosal and cellular immunity in mice. Moreover, the mice in the immunized group had lower lung virus loads and mild lung pathological damages following the challenge with RSV A or RSV B subtype as compared with the control group.Conclusions:A single-dose intranasal immunization with PR8NAGecto/WSN induces robust immunity and provide protection against RSV A and B challenges in mice. This study provides new ideas and reference for the development of novel mucosal vaccines against RSV.
